GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » Quick Ratio

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Quick Ratio

: 4.07 (As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Corvus Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2023 was 4.07.

Corvus Pharmaceuticals has a quick ratio of 4.07. It generally indicates good short-term financial strength.

The historical rank and industry rank for Corvus Pharmaceuticals's Quick Ratio or its related term are showing as below:

CRVS' s Quick Ratio Range Over the Past 10 Years
Min: 3.73   Med: 7.56   Max: 31.16
Current: 4.07

During the past 10 years, Corvus Pharmaceuticals's highest Quick Ratio was 31.16. The lowest was 3.73. And the median was 7.56.

CRVS's Quick Ratio is ranked better than
54.05% of 1554 companies
in the Biotechnology industry
Industry Median: 3.58 vs CRVS: 4.07

Corvus Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Corvus Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.76 3.73 7.36 4.06 4.07

Corvus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.06 4.29 4.82 4.53 4.07

Competitive Comparison

For the Biotechnology subindustry, Corvus Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corvus Pharmaceuticals Quick Ratio Distribution

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Quick Ratio falls into.



Corvus Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Corvus Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(27.956-0)/6.869
=4.07

Corvus Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(27.956-0)/6.869
=4.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corvus Pharmaceuticals  (NAS:CRVS) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Corvus Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corvus Pharmaceuticals (Corvus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
Executives
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
William Benton Jones officer: See Remarks 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Leiv Lea officer: Chief Financial Officer PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Miller Richard A Md director, officer: President and CEO PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell director 1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher officer: Chief Medical Officer 863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould director, 10 percent owner C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy officer: EVP Discovery Research CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt officer: SVP, Chief Business Officer 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner officer: V.P., Chemistry Research 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Headlines

From GuruFocus

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

By GuruFocusNews GuruFocusNews 06-19-2022

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

By GuruFocusNews GuruFocusNews 07-09-2022